MUSC Cardiology
D

SGLT2 Inhibitors in HFpEF: Sifting Through Murky Data

By MUSC Cardiology FEATURING Daniel Silverman
By MUSC Cardiology FEATURING Daniel Silverman
902 views
November 9, 2022
1 Comment
Login to view comments. Click here to Login

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Related Content

AUTOPLAY
06:38
Allan Jaffe

What Does Elevated Troponin Mean in COVID-19?

16:57
William White

Ambulatory Blood Pressure Monitoring

64:45
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

Primer on Diabetes Management

Feat. S. Inzucchi
20:48
Michael Gallagher

Cardiac CT in 2023: From Anatomy to Physiology to Plaque Burden and …

11:37
ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich
28:13
National Lipid Association

New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty…

Feat. R. Mason
11:25
ACC 2023 Conference Coverage

ACC 2023: SGLT2i Use - Dos and Don'ts

Feat. A. Armbruster
10:12
AHA 2022 Conference Coverage

AHA 2022: Chlorthalidone Compared to Hydrochlorothiazide for the Pre…

Feat. A. Ishani
18:43
ASPC 2019 Congress on CVD Prevention

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

Feat. R. DeFronzo
26:01
Cardiology Fiesta 2017

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Feat. R. DeFronzo
27:14
MUSC Cardiology

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

Feat. R. Mentz
45:45
Houston Methodist DeBakey Heart and Vascular Center

Directions of Cardiology in the Next Decade: 2022-2032

Feat. E. Braunwald
17:44
Rita Jermyn

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

15:40
ACC 2022 Conference Coverage

ACC 2022: Triple Therapy - When to Use and How Long

Feat. D. Kumbhani
27:24
Cardiometabolic Health Congress (CMHC)

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Feat. L. Sloan
10:41
Houston Methodist DeBakey Heart and Vascular Center

2020 High Blood Pressure Guidelines: When Is BP Too High?

Feat. A. Marie Navar
13:07
Michelle Kittleson

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

09:52
AHA 2022 Conference Coverage

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

Feat. R. Mentz
12:00
"Princeton 4: PDE5 Inhibitors and Cardiac Health Symposium.” Huntington Medical Research Institutes, Pasadena, CA. Friday, March 10th, 2023.

Neurovascular Mechanisms in Female Sexual Arousal Disorders and Pote…

Feat. N. Kim
42:27
Physicians Committee for Responsible Medicine

Hypertension Management & Nutrition: What Are the Key Nutrients …

Feat. V. Rahman